fostamatinib Articles
AstraZeneca presents mixed data on fostamatinib in RA
13 December 2012
Rheumatoid arthritis drug market forecast to grow modestly to $15.2 billion in 2021
16 September 2012
AstraZeneca's fostamatinib safe, but not effective, in RA patients unresponsive to biologic agents
31 January 2011
AstraZeneca/Rigel’s fostamatinib shows positive response in rheumatoid arthritis in Ph IIb study
22 September 2010
Showing 1-8 of 8 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
